Starton Therapeutics Inc. announced the appointment of Moses Dodo to its Board of Directors. Most recently, Moses Dodo served as the Chairman, Bupa Global LATAM spearheading corporate development and inorganic growth, particularly in Brazil, where he also had direct business accountability. He led the effort to deliver significant growth ambition in the market, in funding and innovative healthcare provision, while leading the overall regional governance for the various Group companies in the USA and all Latin America.

Prior to the Chairman role, Moses was General Manager of BGLA, overseeing one of the largest international private medical insurance (IPMI) portfoli os in the region with offices in Brazil, Mexico, Ecuador, Panama, Guatemala, Dominican Republic, T&T, Colombia, Bolivia, and Chile as well as licenses and portfolios in several countries in Central America and the Caribbean. He was also the CEO and Chairma n of Amedex Bermuda, a Life Insurance company. Moses served as a Board member of HtH Geoblue, a partnership with the Blue Cross Blue Shield offering IPMI in the USA.

During the past 7 years, he led, among other initiatives, the acquisition and integration of CarePlus, the leading premium health insurance company in Brazil offering health insurance plans to more than 400 companies, as well as Dental funding and provision, occupational health, and telemedicine. Moses joined Bupa following 6 successful years a t Haitong Bank (formerly Espirito Santo Investment Bank) where he served as the Senior Managing Director and Board member responsible for all North American operations, including the offices in New York and Mexico City. Previously, Moses also served as General Manager and Divisional Board member for WestLB Bank in New York, from 2001 until 2007, after building his banking career for 17 years in WestLB do Brazil, where he served as CEO from 1995 until moving to New York.

Throughout his 35+ year career focused on the USA and Latin America, he has built strong relationships with regulators, media, government, corporate, distributors, and industry leaders. He is known for his diplomatic skills and collaborative partnerships that lead to mutually beneficial outco mes. His passion for leading multi -national and high-performing teams is viewed as one of his greatest strengths.

Mr. Dodo holds a bachelor's degree in Business Administration & Finance from Fundação Armando Alvares Penteado, Sao Paulo, Brazil. He is a dua l citizen of Brazil and United States and speaks English, Spanish, Portuguese, French, and Italian. He and his family reside in south Florida, where he is active in the community.

Mr. Dodo's appointment to the Board is expected to be formalized following s hareholder approval. Mr. Dodo will replace Cidnee Vaykovich, Starton Therapeutics' Chief Operating Officer, who is resigning from her role as Director and will continue to serve as an Officer of the Company and Secretary to the Board.